Bone metabolism and adipokines: Are there perspectives for bone diseases drug discovery?

Expert Opinion on Drug Discovery

Volumn 9, Issue 8, 2014, Pages 945-957

  Scotece, Morena ^a   Conde, Javier ^a   Abella, Vanessa ^a,b   López, Verónica ^a   Pino, Jesús ^a   Lago, Francisca ^a   Gómez Reino, Juan J ^a   Gualillo, Oreste ^a  

^a University Hospital of Santiago de Compostela   (Spain)

^b UNIVERSITY OF A CORUÑA   (Spain)

Author keywords

Adipokines; Bone; Fat mass; Osteoporosis

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; APELIN; CHEMERIN; LEPTIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; VASPIN;

BONE DISEASE; BONE METABOLISM; FAT MASS; FRACTURE; IMMUNE RESPONSE; INFLAMMATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; WHITE ADIPOSE TISSUE; ANIMAL; BONE; BONE DISEASES; DRUG DESIGN; DRUG DEVELOPMENT; HUMAN; METABOLISM;

ADIPOKINES; ADIPOSE TISSUE, WHITE; ANIMALS; BONE AND BONES; BONE DISEASES; DRUG DESIGN; DRUG DISCOVERY; HUMANS; INFLAMMATION;

EID: 84904822674     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.922539     Document Type: Review

References (139)

1. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32
2. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347-55
3. Trayhurn P, Wood IS. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans 2005;33:1078-81
4. Ralston SH, de Crombrugghe B. Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev 2006;20:2492-506
5. Lim S, Joung H, Shin CS, et al. Body composition changes with age have gender-specific impacts on bone mineral density. Bone 2004;35:792-8
6. Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-6
7. Glauber HS, Vollmer WM, Nevitt MC, et al. Body weight versus body fat distribution, adiposity, and frame size as predictors of bone density. J Clin Endocrinol Metab 1995;80:1118-23
8. Lenchik L, Register TC, Hsu FC, et al. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone 2003;33:646-51
9. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11:327-32
10. Dumond H, Presle N, Terlain B, et al. Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum 2003;48:3118-29
11. Morroni M, De Matteis R, Palumbo C, et al. In vivo leptin expression in cartilage and bone cells of growing rats and adult humans. J Anat 2004;205:291-6
12. Presle N, Pottie P, Dumond H, et al. Differential distribution of adipokines between serum and synovial fluid in patients with osteoarthritis. Contribution of joint tissues to their articular production. Osteoarthritis Cartilage 2006;14:690-5
13. Simopoulou T, Malizos KN, Iliopoulos D, et al. Differential expression of leptin and leptin's receptor isoform (Ob-Rb) mRNA between advanced and minimally affected osteoarthritic cartilage; effect on cartilage metabolism. Osteoarthritis Cartilage 2007;15:872-83
14. Iliopoulos D, Malizos KN, Tsezou A. Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention. Ann Rheum Dis 2007;66:1616-21
15. Jarvinen K, Vuolteenaho K, Nieminen R, et al. Selective iNOS inhibitor 1400W enhances anti-catabolic IL-10 and reduces destructive MMP-10 in OA cartilage. Survey of the effects of 1400W on inflammatory mediators produced by OA cartilage as detected by protein antibody array. Clin Exp Rheumatol 2008;26:275-82
16. Sinha MK, Sturis J, Ohannesian J, et al. Ultradian oscillations of leptin secretion in humans. Biochem Biophys Res Commun 1996;228:733-8
17. Chilliard Y, Bonnet M, Delavaud C, et al. Leptin in ruminants. Gene expression in adipose tissue and mammary gland, and regulation of plasma concentration. Domest Anim Endocrinol 2001;21:271-95
18. Otero M, Lago R, Gomez R, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1198-201
19. Reid IR. Fat and bone. Arch Biochem Biophys 2010;503:20-7
20. Gomez-Ambrosi J, Rodriguez A, Catalan V, et al. The bone-adipose axis in obesity and weight loss. Obes Surg 2008;18:1134-43
21. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100:197-207
22. Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111:305-17
23. Elefteriou F, Ahn JD, Takeda S, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005;434:514-20
24. Steppan CM, Crawford DT, Chidsey-Frink KL, et al. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 2000;92:73-8
25. Cornish J, Callon KE, Bava U, et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 2002;175:405-15
26. Balthasar N, Coppari R, McMinn J, et al. Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis. Neuron 2004;42:983-91
27. Motyl KJ, Rosen CJ. Understanding leptin-dependent regulation of skeletal homeostasis. Biochimie 2012;94:2089-96
28. Myers MG Jr, Heymsfield SB, Haft C, et al. Challenges and opportunities of defining clinical leptin resistance. Cell Metab 2012;15:150-6
29. Maggio AB, Belli DC, Puigdefabregas JW, et al. High bone density in obese adolescents is related to fat mass and serum leptin concentrations. J Pediatr Gastroenterol Nutr 2014. [Epub ahead of print]
30. Liu SQ, Wu J, Mo J, et al. [Serum leptin level and its association with bone mineral density in obese children]. Zhongguo Dang Dai Er Ke Za Zhi 2009;11:745-8
31. Reid IR. Obesity and osteoporosis. Ann Endocrinol (Paris) 2006;67:125-9
32. Silva HG, Mendonca LM, Conceicao FL, et al. Influence of obesity on bone density in postmenopausal women. Arq Bras Endocrinol Metabol 2007;51:943-9
33. Albala C, Yanez M, Devoto E, et al. Obesity as a protective factor for postmenopausal osteoporosis. Int J Obes Relat Metab Disord 1996;20:1027-32
34. Zhao LJ, Liu YJ, Liu PY, et al. Relationship of obesity with osteoporosis. J Clin Endocrinol Metab 2007;92:1640-6
35. Zhao LJ, Jiang H, Papasian CJ, et al. Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J Bone Miner Res 2008;23:17-29
36. Migliaccio S, Greco EA, Fornari R, et al. Is obesity in women protective against osteoporosis? Diabetes Metab Syndr Obes 2011;4:273-82
37. Bjornholm M, Munzberg H, Leshan RL, et al. Mice lacking inhibitory leptin receptor signals are lean with normal endocrine function. J Clin Invest 2007;117:1354-60
38. Shi Y, Yadav VK, Suda N, et al. Dissociation of the neuronal regulation of bone mass and energy metabolism by leptin in vivo. Proc Natl Acad Sci USA 2008;105:20529-33
39. Fujita Y, Watanabe K, Maki K. Serum leptin levels negatively correlate with trabecular bone mineral density in high-fat diet-induced obesity mice. J Musculoskelet Neuronal Interact 2012;12:84-94
40. Fisher A, Srikusalanukul W, Davis M, et al. Interactions between serum adipokines and osteocalcin in older patients with hip fracture. Int J Endocrinol 2012;2012:684323
41. Campos RM, de Mello MT, Tock L, et al. Interaction of bone mineral density, adipokines and hormones in obese adolescents girls submitted in an interdisciplinary therapy. J Pediatr Endocrinol Metab 2013;26:663-8
42. Lee HJ, Kim H, Ku SY, et al. Association between polymorphisms in leptin, leptin receptor, and beta-adrenergic receptor genes and bone mineral density in postmenopausal Korean women. Menopause 2013;21:67-73
43. Ye XL, Lu CF. Association of polymorphisms in the leptin and leptin receptor genes with inflammatory mediators in patients with osteoporosis. Endocrine 2013;44:481-8
44. Zhang J, Li T, Xu L, et al. Leptin promotes ossification through multiple ways of bone metabolism in osteoblast: a pilot study. Gynecol Endocrinol 2013;29:758-62
45. Liu GY, Liang QH, Cui RR, et al. Leptin promotes the osteoblastic differentiation of vascular smooth muscle cells from female mice by increasing RANKL expression. Endocrinology 2014;155:558-67
46. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-51
47. Oh DK, Ciaraldi T, Henry RR. Adiponectin in health and disease. Diabetes Obes Metab 2007;9:282-9
48. Stumvoll M, Tschritter O, Fritsche A, et al. Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes 2002;51:37-41
49. Whitehead JP, Richards AA, Hickman IJ, et al. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006;8:264-80
50. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-9
51. Yamauchi T, Nio Y, Maki T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007;13:332-9
52. Oshima K, Nampei A, Matsuda M, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 2005;331:520-6
53. Shinoda Y, Yamaguchi M, Ogata N, et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 2006;99:196-208
54. Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone 2004;35:842-9
55. Luo XH, Guo LJ, Yuan LQ, et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 2005;309:99-109
56. Kanazawa I. Adiponectin in metabolic bone disease. Curr Med Chem 2012;19:5481-92
57. Huang CY, Lee CY, Chen MY, et al. Adiponectin increases BMP-2 expression in osteoblasts via AdipoR receptor signaling pathway. J Cell Physiol 2010;224:475-83
58. Luo XH, Guo LJ, Xie H, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 2006;21:1648-56
59. Lee YA, Ji HI, Lee SH, et al. The role of adiponectin in the production of IL-6, IL-8, VEGF and MMPs in human endothelial cells and osteoblasts: implications for arthritic joints. Exp Mol Med 2014;46:e72
60. Kajimura D, Lee HW, Riley KJ, et al. Adiponectin regulates bone mass via opposite central and peripheral mechanisms through FoxO1. Cell Metab 2013;17:901-15
61. Williams GA, Wang Y, Callon KE, et al. In vitro and in vivo effects of adiponectin on bone. Endocrinology 2009;150:3603-10
62. Wang F, Wang PX, Wu XL, et al. Deficiency of adiponectin protects against ovariectomy-induced osteoporosis in mice. PLoS One 2013;8:e68497
63. Biver E, Salliot C, Combescure C, et al. Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:2703-13
64. Basurto L, Galvan R, Cordova N, et al. Adiponectin is associated with low bone mineral density in elderly men. Eur J Endocrinol 2009;160:289-93
65. Frost M, Abrahamsen B, Nielsen TL, et al. Adiponectin and peak bone mass in men: a cross-sectional, population-based study. Calcif Tissue Int 2010;87:36-43
66. Kanazawa I, Yamaguchi T, Yamamoto M, et al. Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol 2009;160:265-73
67. Michaelsson K, Lind L, Frystyk J, et al. Serum adiponectin in elderly men does not correlate with fracture risk. J Clin Endocrinol Metab 2008;93:4041-7
68. Kanazawa I, Yamaguchi T, Sugimoto T. Baseline serum total adiponectin level is positively associated with changes in bone mineral density after 1-year treatment of type 2 diabetes mellitus. Metabolism 2010;59:1252-6
69. King GA, Deemer SE, Thompson DL. Relationship between leptin, adiponectin, bone mineral density, and measures of adiposity among pre-menopausal Hispanic and Caucasian women. Endocr Res 2010;35:106-17
70. Okuno S, Ishimura E, Norimine K, et al. Serum adiponectin and bone mineral density in male hemodialysis patients. Osteoporos Int 2012;23:2027-35
71. Samal B, Sun Y, Stearns G, et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431-7
72. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-30
73. Friebe D, Neef M, Kratzsch J, et al. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 2011;54:1200-11
74. Catalan V, Gomez-Ambrosi J, Rodriguez A, et al. Association of increased visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. Nutr Metab Cardiovasc Dis 2011;21:245-53
75. Curat CA, Wegner V, Sengenes C, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006;49:744-7
76. Fukuhara A, Matsuda M, Nishizawa M, et al. Retraction. Science 2007;318:565
77. Jia SH, Li Y, Parodo J, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004;113:1318-27
78. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-58
79. Xie H, Tang SY, Luo XH, et al. Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 2007;80:201-10
80. Venkateshaiah SU, Khan S, Ling W, et al. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity. Exp Hematol 2013;41:547-57.e2
81. Peng XD, Xie H, Zhao Q, et al. Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. Clin Chim Acta 2008;387:31-5
82. Zhang H, Xie H, Zhao Q, et al. Relationships between serum adiponectin, apelin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in post-menopausal Chinese women. J Endocrinol Invest 2010;33:707-11
83. Gruodyte R, Jurimae J, Cicchella A, et al. Adipocytokines and bone mineral density in adolescent female athletes. Acta Paediatr 2010;99:1879-84
84. Tohidi M, Akbarzadeh S, Larijani B, et al. Omentin-1, visfatin and adiponectin levels in relation to bone mineral density in Iranian postmenopausal women. Bone 2012;51:876-81
85. Iacobellis G, Iorio M, Napoli N, et al. Relation of adiponectin, visfatin and bone mineral density in patients with metabolic syndrome. J Endocrinol Invest 2011;34:e12-15
86. Sucunza N, Barahona MJ, Resmini E, et al. A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly. J Clin Endocrinol Metab 2009;94:3889-96
87. Briana DD, Boutsikou M, Boutsikou T, et al. Associations of novel adipocytokines with bone biomarkers in intra uterine growth-restricted fetuses/neonates at term. J Matern Fetal Neonatal Med 2013. [Epub ahead of print]
88. Li Y, He X, He J, et al. Nicotinamide phosphoribosyltransferase (Nampt) affects the lineage fate determination of mesenchymal stem cells: a possible cause for reduced osteogenesis and increased adipogenesis in older individuals. J Bone Miner Res 2011;26:2656-64
89. Moschen AR, Geiger S, Gerner R, et al. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Mutat Res 2010;690:95-101
90. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12
91. Ghosh S, Singh AK, Aruna B, et al. The genomic organization of mouse resistin reveals major differences from the human resistin: functional implications. Gene 2003;305:27-34
92. Patel L, Buckels AC, Kinghorn IJ, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003;300:472-6
93. Fain JN, Cheema PS, Bahouth SW, et al. Resistin release by human adipose tissue explants in primary culture. Biochem Biophys Res Commun 2003;300:674-8
94. Rajala MW, Obici S, Scherer PE, et al. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003;111:225-30
95. Satoh H, Nguyen MT, Miles PD, et al. Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats. J Clin Invest 2004;114:224-31
96. Kim KH, Zhao L, Moon Y, et al. Dominant inhibitory adipocyte-specific secretory factor (ADSF)/resistin enhances adipogenesis and improves insulin sensitivity. Proc Natl Acad Sci USA 2004;101:6780-5
97. Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. Trends Endocrinol Metab 2011;22:259-65
98. Kunnari AM, Savolainen ER, Ukkola OH, et al. The expression of human resistin in different leucocyte lineages is modulated by LPS and TNFalpha. Regul Pept 2009;157:57-63
99. Lehrke M, Reilly MP, Millington SC, et al. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004;1:e45
100. Tarkowski A, Bjersing J, Shestakov A, et al. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med 2010;14:1419-31
101. Steppan CM, Wang J, Whiteman EL, et al. Activation of SOCS-3 by resistin. Mol Cell Biol 2005;25:1569-75
102. Pirvulescu M, Manduteanu I, Gan AM, et al. A novel pro-inflammatory mechanism of action of resistin in human endothelial cells: up-regulation of SOCS3 expression through STAT3 activation. Biochem Biophys Res Commun 2012;422:321-6
103. Thommesen L, Stunes AK, Monjo M, et al. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem 2006;99:824-34
104. Vondracek SF, Voelkel NF, McDermott MT, et al. The relationship between adipokines, body composition, and bone density in men with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2009;4:267-77
105. Oh KW, Lee WY, Rhee EJ, et al. The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men. Clin Endocrinol (Oxf) 2005;63:131-8
106. Fisher A, Southcott E, Li R, et al. Serum resistin in older patients with hip fracture: relationship with comorbidity and biochemical determinants of bone metabolism. Cytokine 2012;56:157-66
107. Mohiti-Ardekani J, Soleymani-Salehabadi H, Owlia MB, et al. Relationships between serum adipocyte hormones (adiponectin, leptin, resistin), bone mineral density and bone metabolic markers in osteoporosis patients. J Bone Miner Metab 2013. [Epub ahead of print]
108. Barbour KE, Zmuda JM, Boudreau R, et al. Adipokines and the risk of fracture in older adults. J Bone Miner Res 2011;26:1568-76
109. Johansson H, Oden A, Lerner UH, et al. High serum adiponectin predicts incident fractures in elderly men: osteoporotic fractures in men (MrOS) Sweden. J Bone Miner Res 2012;27:1390-6
110. Borregaard N, Cowland JB. Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. Biometals 2006;19:211-15
111. Chakraborty S, Kaur S, Guha S, et al. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta 2012;1826:129-69
112. Conde J, Gomez R, Bianco G, et al. Expanding the adipokine network in cartilage: identification and regulation of novel factors in human and murine chondrocytes. Ann Rheum Dis 2011;70:551-9
113. Triebel S, Blaser J, Reinke H, et al. A 25 kDa alpha 2-microglobulin- related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett 1992;314:386-8
114. Kjeldsen L, Bainton DF, Sengelov H, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils. Blood 1994;83:799-807
115. Kjeldsen L, Cowland JB, Borregaard N. Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta 2000;1482:272-83
116. Kjeldsen L, Johnsen AH, Sengelov H, et al. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993;268:10425-32
117. Devireddy LR, Teodoro JG, Richard FA, et al. Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 2001;293:829-34
118. Chu ST, Lin HJ, Huang HL, et al. The hydrophobic pocket of 24p3 protein from mouse uterine luminal fluid: fatty acid and retinol binding activity and predicted structural similarity to lipocalins. J Pept Res 1998;52:390-7
119. Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 1997;45:17-23
120. Yang J, Goetz D, Li JY, et al. An iron delivery pathway mediated by a lipocalin. Mol Cell 2002;10:1045-56
121. Goetz DH, Holmes MA, Borregaard N, et al. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002;10:1033-43
122. Richardson DR. 24p3 and its receptor: dawn of a new iron age? Cell 2005;123:1175-7
123. Devireddy LR, Gazin C, Zhu X, et al. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 2005;123:1293-305
124. Bartsch S, Tschesche H. Cloning and expression of human neutrophil lipocalin cDNA derived from bone marrow and ovarian cancer cells. FEBS Lett 1995;357:255-9
125. Costa D, Biticchi R, Negrini S, et al. Lipocalin-2 controls the expression of SDF-1 and the number of responsive cells in bone. Cytokine 2010;51:47-52
126. Costa D, Lazzarini E, Canciani B, et al. Altered bone development and turnover in transgenic mice over-expressing lipocalin-2 in bone. J Cell Physiol 2013;228:2210-21
127. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003;198:977-85
128. Gantz I, Konda Y, Yang YK, et al. Molecular cloning of a novel receptor (CMKLR1) with homology to the chemotactic factor receptors. Cytogenet Cell Genet 1996;74:286-90
129. Berg V, Sveinbjornsson B, Bendiksen S, et al. Human articular chondrocytes express ChemR23 and chemerin; ChemR23 promotes inflammatory signalling upon binding the ligand chemerin(21-157). Arthritis Res Ther 2010;12:R228
130. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007;148:4687-94
131. Luangsay S, Wittamer V, Bondue B, et al. Mouse ChemR23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model. J Immunol 2009;183:6489-99
132. Muruganandan S, Roman AA, Sinal CJ. Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stem cells. J Bone Miner Res 2010;25:222-34
133. Muruganandan S, Dranse HJ, Rourke JL, et al. Chemerin neutralization blocks hematopoietic stem cell osteoclastogenesis. Stem Cells 2013;31:2172-82
134. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251:471-6
135. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005;146:1764-71
136. Wattanachanya L, Lu WD, Kundu RK, et al. Increased bone mass in mice lacking the adipokine apelin. Endocrinology 2013;154:2069-80
137. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005;102:10610-15
138. Kamio N, Kawato T, Tanabe N, et al. Vaspin attenuates RANKL-induced osteoclast formation in RAW264.7 cells. Connect Tissue Res 2013;54:147-52
139. Zhu X, Jiang Y, Shan PF, et al. Vaspin attenuates the apoptosis of human osteoblasts through ERK signaling pathway. Amino Acids 2013;44:961-8